Walpar Nutritions Ltd. demonstrates impressive growth metrics, particularly in revenue and earnings, positioning it favorably compared to its peers. However, its valuation ratios suggest caution, as the company is still in the early stages of profitability. While several peers exhibit strong performance, some are overvalued based on their earnings potential, making Walpar a potential value pick within the sector.

• • Walpar shows the highest revenue growth (YoY) at 77.91%.
• • Cipla leads in profitability with the highest ROE of 16.63%.
• • Sun Pharma has the highest PE ratio at 87.59, indicating overvaluation.
• • Divi's Labs shows concerning revenue declines over 3 years, highlighting potential instability.